Tomohiro TADA
 | Tomohiro TADA CEO AI Medical Service Inc., Japan |
Biosketch
Dr Tomohiro TADA is the CEO of AI Medical Service Inc., the chairperson of Tada Tomohiro The Institute of Gastroenterology & Proctology, and Visiting Lecturer, Department of Surgical Oncology, Graduate School of Medicine, the University of Tokyo Hospital.
Dr TADA received his M.D. of school of medicine in 1996 and Ph.D. of department of surgery in 2005 from the University of Tokyo. He trained in Colorectal Surgery at the University of Tokyo Hospital.
He has written several books including ‘Patient-friendly “painless” colonoscopy insertion method,’ and also reported numerous research papers on endoscopic AI development, especially the world’s first paper on detection AI for gastric cancer.
AI Medical Service Inc.
This company has been developing an AI software which supports endoscopic diagnosis of Gastrointestinal cancer.
AIM is dedicated to support endoscopists which has driven us to begin our research. They are committed to create what is truly useful in the clinical environment to save patients around the globe.
In December 2023, AIM developed the detection AI system for gastric cancer, named gastroAI-model G (registration number: 30500BZX00297000), and obtained pharmaceutical approval in Japan. Moreover, AIM announced that this gastroAI-model G was commercialized in March 2024. In February 2024, AIM also obtained pharmaceutical approval in Singapore. In 2024 April, this product also got medical approval in Brazil.